康弘药业
(002773)
| 流通市值：150.06亿 | | | 总市值：201.31亿 |
| 流通股本：6.87亿 | | | 总股本：9.21亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,046,478,561.32 | 4,585,133,789.58 | 3,623,865,721.06 | 2,453,661,937.96 |
| 营业收入 | 1,046,478,561.32 | 4,585,133,789.58 | 3,623,865,721.06 | 2,453,661,937.96 |
| 二、营业总成本 | 690,570,560.84 | 3,278,743,141.86 | 2,438,543,787.09 | 1,619,188,513.48 |
| 营业成本 | 118,653,783.45 | 465,414,594.12 | 350,477,855.01 | 246,705,592.31 |
| 税金及附加 | 18,605,409.32 | 59,059,726.52 | 43,239,824.74 | 31,138,857.73 |
| 销售费用 | 367,061,985.03 | 1,721,166,768.03 | 1,395,399,651.37 | 925,059,691.84 |
| 管理费用 | 111,821,677.94 | 552,780,072.59 | 356,795,412.74 | 231,855,999.31 |
| 研发费用 | 86,772,265.16 | 533,093,330.63 | 334,157,560.21 | 214,615,347.81 |
| 财务费用 | -12,344,560.06 | -52,771,350.03 | -41,526,516.98 | -30,186,975.52 |
| 其中:利息收入 | 12,630,866.48 | 53,345,706.75 | 41,612,234.52 | 30,349,352.3 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 192,600 | 550,600 | -720,200 | -1,884,200 |
| 加:投资收益 | -214,779.77 | 36,236,443.63 | 11,064,472.92 | 8,123,311.62 |
| 资产处置收益 | -54,652.96 | 9,782.42 | 8,453.87 | 3,472.82 |
| 资产减值损失(新) | - | -7,560,810.49 | -1,217,979.11 | -688,329.89 |
| 信用减值损失(新) | -532,473.98 | -424,902.59 | -535,584.73 | -511,588.1 |
| 其他收益 | 3,970,171.18 | 42,163,692.87 | 34,172,447.19 | 25,087,140.32 |
| 四、营业利润 | 359,268,864.95 | 1,377,365,453.56 | 1,228,093,544.11 | 864,603,231.25 |
| 加:营业外收入 | 177,945.9 | 17,312,300.77 | 2,325,909.72 | 782,347.84 |
| 减:营业外支出 | 934,927.73 | 38,564,204.5 | 21,968,715.88 | 12,923,284.35 |
| 五、利润总额 | 358,511,883.12 | 1,356,113,549.83 | 1,208,450,737.95 | 852,462,294.74 |
| 减:所得税费用 | 55,308,519.39 | 210,609,936.12 | 187,326,343.02 | 130,598,260.91 |
| 六、净利润 | 303,203,363.73 | 1,145,503,613.71 | 1,021,124,394.93 | 721,864,033.83 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 303,203,363.73 | 1,145,503,613.71 | 1,021,124,394.93 | 721,864,033.83 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 307,482,134.44 | 1,162,966,864.98 | 1,032,906,564.53 | 729,699,133.47 |
| 少数股东损益 | -4,278,770.71 | -17,463,251.27 | -11,782,169.6 | -7,835,099.64 |
| 扣除非经常损益后的净利润 | 304,666,792.77 | 1,117,941,258.68 | 1,023,661,750.61 | 722,555,631.64 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.33 | 1.26 | 1.12 | 0.79 |
| (二)稀释每股收益 | 0.33 | 1.26 | 1.12 | 0.79 |
| 八、其他综合收益 | 273,714.13 | -126,281.75 | -322,319.27 | -64,852.09 |
| 归属于母公司股东的其他综合收益 | 273,714.13 | -126,281.75 | -322,319.27 | -64,852.09 |
| 九、综合收益总额 | 303,477,077.86 | 1,145,377,331.96 | 1,020,802,075.66 | 721,799,181.74 |
| 归属于母公司股东的综合收益总额 | 307,755,848.57 | 1,162,840,583.23 | 1,032,584,245.26 | 729,634,281.38 |
| 归属于少数股东的综合收益总额 | -4,278,770.71 | -17,463,251.27 | -11,782,169.6 | -7,835,099.64 |
| 公告日期 | 2026-04-23 | 2026-04-23 | 2025-10-29 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |